Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma

e16134 Background: In experimental systems, interference with coagulation can affect tumor biology. We suggested that abnormal coagulation could be a negative predictor for response to immunotherapy and survival among patients with metastatic renal cell carcinoma (MRCC). METHODS To address this issue, retrospective analysis of 289 previously untreated MRCC patients entering on institutional review board-approved clinical trials was conducted between 2003 and 2006. In addition, two groups of MRCC patients with (n = 28) or without (n = 28) hypercoagulability were compared in a case-control study. Baseline and treatment characteristics were well balanced. RESULTS Hypercoagulability was present at treatment start in 40% of patients. Median baseline fibrinogen was 6.2 mg/dl. Serious disorders were found in 68% of patients. Abnormal coagulation was strongly associated with a number of metastatic sites (2 and more metastatic sites vs. 0-1 (p = 0.001). Patients with high extent of hypercoagulability had significantly higher number of metastatic sites (p = 0.02). On univariate analysis, patients with hypercoagulability had significantly shorter overall survival than patients with normal coagulation; median survivals of 8.9 and 16.3, respectively (p = 0.001). Short survival and low response rate also were significantly associated with hypercoagulability in a case-control study. Median cancer-specific survival was 8.2 months and 14.6 months, respectively (p = 0.0011). Disease control rate (overall response + stable disease) was significantly higher in patients with normal coagulation: 71.4 versus 42.9% (p = 0.003). We did not reveal VTE-related deaths. CONCLUSIONS Hypercoagulability disorders were found to be prognostic factor for response rate to systemic therapy and survival in patients with MRCC. No significant financial relationships to disclose.